相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma
Yinli Yang et al.
CANCER GENE THERAPY (2021)
NRF2 in human neoplasm: Cancer biology and potential therapeutic target
Yang Liu et al.
PHARMACOLOGY & THERAPEUTICS (2021)
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers
Hiromi Watanabe et al.
CANCER SCIENCE (2021)
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Caicun Zhou et al.
CLINICAL CANCER RESEARCH (2021)
Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
Na Zhou et al.
ONCOLOGIST (2021)
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition
Sophia Daum et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer
Pingping Liang et al.
ADVANCED MATERIALS (2021)
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer
Yufei Yang et al.
CANCER COMMUNICATIONS (2021)
Apatinib suppresses lung cancer stem-like cells by complex interplay between β-catenin signaling and mitochondrial ROS accumulation
Jianyun Zhu et al.
CELL DEATH DISCOVERY (2021)
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence
Elisabetta Grillo et al.
CANCER LETTERS (2021)
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Hongyun Zhao et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling
Zhi C. Tian et al.
JOURNAL OF ORTHOPAEDIC TRANSLATION (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis
Manman Deng et al.
EXPERIMENTAL CELL RESEARCH (2020)
Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance
Nazila Fathi Maroufi et al.
LIFE SCIENCES (2020)
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Qiaohong Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
Julian Mohrherr et al.
CANCERS (2020)
Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors
Mangala Hegde et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
Zhonghan Zhang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways
Bingxin Zheng et al.
FRONTIERS IN ONCOLOGY (2020)
Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
Jiangang Zhao et al.
FRONTIERS IN ONCOLOGY (2020)
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Xiaomin Cai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
Jianmiao Liang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
Yong-An Song et al.
CANCER CELL INTERNATIONAL (2019)
Emerging therapies for non-small cell lung cancer
Chao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
Yanjun Xu et al.
BRITISH JOURNAL OF CANCER (2019)
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
Sehui Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Zhonghan Zhang et al.
CANCER COMMUNICATIONS (2019)
NRF2 addiction in lung cancer cells and its impact on cancer therapy
Ahmed Hammad et al.
CANCER LETTERS (2019)
Apatinib exerts anti-tumour effects on ovarian cancer cells
Jing Ding et al.
GYNECOLOGIC ONCOLOGY (2019)
Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling
Song Wen et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
Bingxin Zheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells
Chenxi Hu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Activation of p62/SQSTM1-Keap1-Nuclear Factor erythroid 2-Related Factor 2 Pathway in Cancer
Yoshinobu Ichimura et al.
FRONTIERS IN ONCOLOGY (2018)
Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer
Haoran Feng et al.
CELL DEATH & DISEASE (2018)
VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy
Sandrina Nobrega-Pereira et al.
CANCER RESEARCH (2018)
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
Fang Li et al.
EUROPEAN JOURNAL OF CANCER (2017)
miR-19 targeting of GSK3β mediates sulforaphane suppression of lung cancer stem cells
Jianyun Zhu et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2017)
Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy
Hanna-Riikka Teppo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Curcumin Suppresses Lung Cancer Stem Cells via Inhibiting Wnt/β-catenin and Sonic Hedgehog Pathways
Jian-Yun Zhu et al.
PHYTOTHERAPY RESEARCH (2017)
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Kuisheng Liu et al.
CELL DEATH & DISEASE (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression
L. Liu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment
Byung-Hak Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
p62 links autophagy and Nrf2 signaling
Tao Jiang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Apatinib for molecular targeted therapy in tumor
Haijun Zhang
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
CD133 expression: a potential prognostic marker for non-small cell lung cancers
Hidenori Mizugaki et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1
Masaaki Komatsu et al.
NATURE CELL BIOLOGY (2010)
Autophagy Suppresses Tumorigenesis through Elimination of p62
Robin Mathew et al.
CELL (2009)
The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer
Virginia Tirino et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2009)
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
Giulia Bertolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
分享论文
